PPARγ deficient breast cancers were insensitive to chemotherapy, but normalization of the abundant tumor vasculature with the anti-angiogenic drug sunitinib increased efficiency of cytostatic chemotherapy. This evidence concerns the gene PPARG and breast cancer.